Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data-Reference-Cited by-同舟云学术

Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data

Published:2022-02 Issue: Volume:Volume 14 Page:623-635
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Miyake Makito^ORCID,Nishimura Nobutaka^ORCID,Shimizu Takuto,Onishi Mikiko,Kuwada Masaomi,Itami Yoshitaka,Inoue Takeshi,Onishi Kenta,Matsumoto Yoshihiro,Yoshida Takanori,Tatsumi Yoshihiro,Shinohara Masatake,Hori Shunta^ORCID,Morizawa Yosuke^ORCID,Gotoh Daisuke^ORCID,Nakai Yasushi,Anai Satoshi,Torimoto Kazumasa^ORCID,Aoki Katsuya,Fujii Tomomi,Tanaka Nobumichi^ORCID,Fujimoto Kiyohide

Publisher

Informa UK Limited

Subject

Oncology

Reference24 articles.

1. Global cancer statistics, 2012

2. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

3. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice

4. Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma

5. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era;World Journal of Urology;2024-05-09

2. Combination therapies targeting different aspects of tumor biology for patients with advanced urothelial carcinoma;Translational Andrology and Urology;2024-05

3. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18

4. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort;Japanese Journal of Clinical Oncology;2023-12-07

5. Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance;BMC Cancer;2023-06-20